CompletedNCT02884544
A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD
Researchers studied HLD100, tracking side effects to assess safety and tolerability in children with ADHD.
Medication studyAges 6–12United States
Understand this study
What did researchers investigate?
Researchers studied HLD100, tracking side effects to assess safety and tolerability in children with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
- Listed locations
- Las VegasSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: August 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 22
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT02884544
- Official title
Show the full official title
Phase II, Open-label, Dose-titration, Safety Study Designed to Determine the Evening Dose of a Novel Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) to Produce Optimal Clinical Effects in Children With ADHD
Recruitment & locations
CompletedLas Vegas
Questions about this study
What did researchers investigate?
Researchers studied HLD100, tracking side effects to assess safety and tolerability in children with ADHD.
Who is behind this study?
The study sponsor is Ironshore Pharmaceuticals and Development, Inc.
Did this study involve medication?
Yes. The study involved medication, including HLD100.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)